Director/PDMR Dealing and Issue of Shares

RNS Number : 2927O

Alpha Growth PLC

29 May 2020

 

Alpha Growth plc

(" Alpha ", or the "Company")

Director/PDMR Dealing and Issue of Shares

Alpha Growth plc (LSE:   ALGW), the financial services specialist in the growing Senior Life Settlement ("SLS") asset class, is pleased to announce certain directors of the Company have purchased ordinary shares in the Company and the issue of 2,000,000 shares for the agreement with Rajiv Rebello and Colva. This satisfies the condition of the Company's agreement with Colva.

Director/PDMR Dealing

The Company is also pleased to announce that the Directors below have subscribed for the Company's shares as follows:

	No. of Shares acquired	Resultant no. of Ordinary Shares	% of Enlarged Issued Share Capital (as enlarged by the Share Issues)
Gobind Sahney	666,667	7,462,500	3.64%
Danny Swick	666,667	2,166,667	1.06%
Jason Sutherland	133,333	133,333	0.07%

Issue of Shares

In relation to the above share issues applications will be made to the Financial Conduct Authority for admission of the new Ordinary Shares to the standard listing segment of the Official List of the Financial Conduct Authority and to London Stock Exchange plc for admission to trading of the New Shares on its main market for listed securities (together, "Admission"). Further announcement will be made as to the date of admission.

Total Voting Rights

Following the issue of the above Shares, the Company's issued share capital will consist of 205,101,673 ordinary shares. Each share has one voting right and no shares are held in treasury; these figures may be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	1.  Gobind Sahney 2.  Daniel Swick 3.  Jason Sutherland
2	Reason for the notification
a)	Position/status	1.  Chairman 2.  Director 3.  Director
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Alpha Growth plc
b)	LEI	213800T46KFT32KYKR91
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary 0.1p GB00BYWKBC49
b)	Nature of the transaction	Subscription
c)	Price(s) and volume(s)	1.  0.015  666,667 2.  0.015  666,667 3.  0.015  133,333
d)	Aggregated information: -  Aggregated volume -  Price	1,466,667 0.015
e)	Date of the transaction	28 May 2020
f)	Place of the transaction	Outside a trading venue

For more information, please visit www.algwplc.com   or contact the following :

Alpha Growth plc	[phone]
Gobind Sahney, Executive Chairman	[e-mail]

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

About Alpha Growth plc

Specialist in Longevity Assets

Alpha Growth plc is a financial advisory business providing specialist consultancy, advisory and supplementary services to institutional and qualified investors globally in the multi-billion dollar market of longevity assets. Building on its well-established network, Alpha Growth has a unique position in the longevity asset services and investment business, as a listed entity with global reach. The Company's strategy is to expand its advisory and business services via acquisitions and joint ventures in the UK and the US to attain commercial scale and provide holistic solutions to alternative institutional investors who are in need of specialised skills and unique access to deploy their financial resource in longevity assets.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

END

 

 

MSCFZGZKGRMGGZZ